A Phase 1 interventional study of AMG 133 in Healthy Participants, sponsored by Amgen. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-25.
Sponsored by Amgen · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to evaluate the pharmacokinetics (PK) of AMG 133 after single subcutaneous (SC) administration in healthy Japanese and Caucasian participants.
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy Japanese participants will receive the low dose of AMG 133 as a SC injection on Day 1 of the study.
Drug: AMG 133
Healthy Japanese participants will receive the medium dose of AMG 133 as a SC injection on Day 1 of the study.
Drug: AMG 133
Healthy Japanese participants will receive the high dose of AMG 133 as a SC injection on Day 1 of the study.
Drug: AMG 133
Healthy Caucasian participants will receive the medium dose of AMG 133 as a SC injection on Day 1 of the study.
Drug: AMG 133
Healthy Caucasian participants will receive the high dose of AMG 133 as a SC injection on Day 1 of the study.
Drug: AMG 133
Solution for SC injection
Also known as: maridebart cafraglutide
Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Cmax of Total AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
AUClast of Total AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
AUCinf of Total AMG 133
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
Time frame: Day 1 pre-dose and 24, 48, 72, 96, 120, 144, 168, 336, 504, 672, 1008, 1344, 1680, 2184, and 2856 hours post-dose
Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE)
A TEAE was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with AMG 133 that started during or after dosing, or started prior to dosing and increased in severity after dosing. Clinically significant changes from baseline in clinical laboratory tests, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.
Time frame: Day 1 to Day 120
Number of Participants With a Positive Anti-AMG 133 Binding Antibody Result
Blood samples were collected at specific times during the study for the measurement of anti-AMG 133 binding antibodies from participants who received AMG 133.
Time frame: Days 1, 15, 29, 57 and 120
Healthy Japanese and Caucasian participants were enrolled at a single center in the United States between 10 September 2021 and 08 April 2022.
| Milestone | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Started | 6 | 7 | 7 | 7 | 7 |
| Received amg 133 | 6 | 7 | 7 | 7 | 7 |
| Completed | 6 | 6 | 7 | 5 | 6 |
| Not completed | 0 | 1 | 0 | 2 | 1 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 2 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 0 | 0 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| μg/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Maximum Observed Plasma Concentration (Cmax) of Intact AMG 133 | 12.3 ± 57.3 | 22.7 ± 24.1 | 44.9 ± 34.6 | 22.5 ± 33.9 | 55.0 ± 26.7 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| μg/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Cmax of Total AMG 133 | 13.2 ± 56.3 | 24.8 ± 25.6 | 48.4 ± 32.0 | 20.8 ± 24.5 | 58.7 ± 24.8 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| h*ug/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero to the Time of Last Quantifiable Concentration (AUClast) of Intact AMG 133 | 10600 ± 45.2 | 19400 ± 36.0 | 33500 ± 20.5 | 17200 ± 42.4 | 35700 ± 31.1 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| h*ug/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| AUClast of Total AMG 133 | 14800 ± 41.8 | 28300 ± 37.2 | 47700 ± 21.1 | 20800 ± 41.4 | 49600 ± 30.9 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| h*ug/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUCinf) of Intact AMG 133 | 10700 ± 44.9 | 19600 ± 36.4 | 33900 ± 20.4 | 17300 ± 43.3 | 36000 ± 31.6 |
Blood samples were collected at specific times during the study for the measurement of plasma concentrations of intact and total AMG 133 by a laboratory.
| h*ug/mL | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| AUCinf of Total AMG 133 | 15600 ± 40.5 | 30100 ± 39.2 | 50100 ± 21.8 | 21800 ± 45.4 | 51500 ± 32.5 |
A TEAE was defined as any untoward medical occurrence in a clinical study participant irrespective of a causal relationship with AMG 133 that started during or after dosing, or started prior to dosing and increased in severity after dosing. Clinically significant changes from baseline in clinical laboratory tests, 12-lead electrocardiograms (ECGs) and vital signs were also reported as TEAEs.
| Participants | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | 6 | 6 | 7 | 7 | 7 |
Blood samples were collected at specific times during the study for the measurement of anti-AMG 133 binding antibodies from participants who received AMG 133.
| Participants | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Number of Participants With a Positive Anti-AMG 133 Binding Antibody Result | 3 | 3 | 3 | 1 | 0 |
Collected over All-cause mortality was collected from enrolment to end of study (median [min,max]: 4.42 months [1.51, 5.42 months]. Serious adverse events and other adverse events were collected from Day 1 to Day 120.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Japanese Participants: AMG 133 Low Dose | 0/6 (0%) | 0/6 (0%) | 6/6 (100%) |
| Japanese Participants: AMG 133 Medium Dose | 0/7 (0%) | 0/7 (0%) | 6/7 (85.7%) |
| Japanese Participants: AMG 133 High Dose | 0/7 (0%) | 1/7 (14.3%) | 7/7 (100%) |
| Caucasian Participants: AMG 133 Medium Dose | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Caucasian Participants: AMG 133 High Dose | 0/7 (0%) | 0/7 (0%) | 7/7 (100%) |
| Event | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| Road traffic accidentInjury, poisoning and procedural complications | 0/6 | 0/7 | 1/7 | 0/7 | 0/7 |
| Cervical spinal stenosisMusculoskeletal and connective tissue disorders | 0/6 | 0/7 | 1/7 | 0/7 | 0/7 |
| Event | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose |
|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/6 | 6/7 | 7/7 | 7/7 | 7/7 |
| VomitingGastrointestinal disorders | 4/6 | 6/7 | 7/7 | 7/7 | 7/7 |
| HeadacheNervous system disorders | 2/6 | 3/7 | 5/7 | 3/7 | 3/7 |
| ParaesthesiaNervous system disorders | 0/6 | 0/7 | 1/7 | 0/7 | 3/7 |
| Decreased appetiteMetabolism and nutrition disorders | 2/6 | 1/7 | 1/7 | 1/7 | 2/7 |
| FatigueGeneral disorders | 0/6 | 0/7 | 2/7 | 0/7 | 0/7 |
| COVID-19Infections and infestations | 0/6 | 0/7 | 0/7 | 2/7 | 2/7 |
| MyalgiaMusculoskeletal and connective tissue disorders | 1/6 | 0/7 | 1/7 | 0/7 | 2/7 |
| Abdominal painGastrointestinal disorders | 1/6 | 0/7 | 0/7 | 0/7 | 0/7 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 1/6 | 0/7 | 0/7 | 0/7 | 1/7 |
Safety Population: Included all participants who received at least 1 dose of AMG 133.
| Age, Continuous(years) | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose | Total |
|---|---|---|---|---|---|---|
| Mean | 57.3 ± 4.80 | 55.0 ± 5.35 | 52.9 ± 13.90 | 43.0 ± 14.59 | 49.0 ± 11.93 | 51.3 ± 11.58 |
| Sex: Female, Male(Participants) | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose | Total |
|---|---|---|---|---|---|---|
| Female | 3 | 3 | 4 | 1 | 2 | 13 |
| Male | 3 | 4 | 3 | 6 | 5 | 21 |
| Ethnicity (NIH/OMB)(Participants) | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose | Total |
|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 2 | 4 | 6 |
| Not Hispanic or Latino | 6 | 7 | 7 | 5 | 3 | 28 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Japanese Participants: AMG 133 Low Dose | Japanese Participants: AMG 133 Medium Dose | Japanese Participants: AMG 133 High Dose | Caucasian Participants: AMG 133 Medium Dose | Caucasian Participants: AMG 133 High Dose | Total |
|---|---|---|---|---|---|---|
| White | 0 | 0 | 0 | 7 | 7 | 14 |
| Japanese | 6 | 7 | 7 | 0 | 0 | 20 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.
Data sharing details ↗ · www.amgen.com
Ran from Sep 2021 to primary completion in Apr 2022, 6 months.
Results were first posted in Feb 2025, 2 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Maridebart cafraglutide